



Application

- Immunization
- FACS
- Elisa

Synonym

ACKR2


Source

Human ACKR2 Full Length Protein (VLP) (AC2-H52P3) is expressed from human 293 cells (HEK293). It contains AA Ala 2 - Ala 384 (Accession # [O00590](#)).

Predicted N-terminus: Asp


Molecular Characterization

- **Structure**



Virus-like particles (VLPs) are protein particles that mimic the shape of viruses but lack a viral genome, and incorporating transmembrane proteins on the external surface.

- **Synthesis Process**



Virus-like particles (VLPs) are non-infectious structures that mimic the shape of viruses but lack a viral genome. During VLP production in cells systems, VLPs self-assemble into 100-200 nm protein particles, and incorporate transmembrane proteins into a VLP-MP complex, resulting in presentation of the protein on the external surface of the VLP. Their repetitive, multivalent surface display and **strong immunogenicity**, making them an excellent candidate for immunization.

Endotoxin

Less than 1.0 EU per µg by the LAL method / rFC method.

Formulation

The VLPs are highly immunogenic, so the immunization strategy should be optimized (antigen dose, regimen and adjuvant).

Supplied as 0.2 µm filtered solution in PBS, Arginine, pH7.4 with trehalose as protectant.

Contact us for customized product form or formulation.

Shipping

This product is supplied and shipped with dry ice, please inquire the shipping cost.

Storage

Please avoid repeated freeze-thaw cycles.

This product is stable after storage at:


- The product **MUST** be stored at -70°C or lower upon receipt;
- -70°C for 12 months under sterile conditions.

ACRO Quality Management System

- [QMS\(ISO, GMP\)](#)
- [Quality Advantages](#)
- [Quality Control Process](#)


*The isotype control of empty/mock VLP (Cat. No. [VLP-N5213](#)) is sold separately and not included in protein, you can follow [the link](#) for product information.

Bioactivity-ELISA



Immobilized Human ACKR2 Full Length Protein (VLP) (Cat. No. AC2-H52P3) at 5 µg/mL (100 µL/well) can bind Anti-ACKR2 Antibody with a linear range of 0.01-0.313 µg/mL (QC tested).

Identity-DLS



The mean peak Radius of VLP is 60-80 nm with more than 95% intensity as determined by dynamic light scattering (DLS).

Background

Atypical chemokine receptor that controls chemokine levels and localization via high-affinity chemokine binding that is uncoupled from classic ligand-driven signal transduction cascades, resulting instead in chemokine sequestration, degradation, or transcytosis. Also known as interceptor (internalizing receptor) or chemokine-scavenging receptor or chemokine decoy receptor. Acts as a receptor for chemokines including CCL2, CCL3, CCL3L1, CCL4, CCL5, CCL7, CCL8, CCL11, CCL13, CCL17, CCL22, CCL23, CCL24, SCYA2/MCP-1, SCYA3/MIP-1-alpha, SCYA5/RANTES and SCYA7/MCP-3. Upon active ligand stimulation, activates a beta-arrestin 1 (ARRB1)-dependent, G protein-independent signaling pathway that results in the phosphorylation of the actin-binding protein cofilin (CFL1) through a RAC1-PAK1-LIMK1 signaling pathway. Activation of this pathway results in up-regulation of ACKR2 from endosomal compartment to cell membrane, increasing its efficiency in chemokine uptake and degradation. By scavenging chemokines in tissues, on the surfaces of lymphatic vessels, and in placenta, plays an essential role in the resolution (termination) of the inflammatory response and in the regulation of adaptive immune responses. Plays a major role in the immune silencing of macrophages during the resolution of inflammation. Acts as a regulator of inflammatory leukocyte interactions with lymphatic endothelial cells (LECs) and is required for immature/mature dendritic cells discrimination by LECs.

Discounts, Gifts,
and more!



www.acrobiosystems.com



5/9/2026